Key Market Indicator:
Welcome our new Research Provider
In the Research & Ratings section, you can access assessments from renowned analyst firms that specialize in the due diligence and valuation of companies that are generally listed on the stock exchange. Starting from the research reports, you can access further research tools and information with just a few mouse clicks, which offer you additional options for obtaining and assessing information.
Thu, 15.10.2026       https://research-hub.de/companies/siemens-energy-ag

Siemens Energy (SE) is set to report Q4 and FY26 results on 11 November. We expect a strong finish, supported by high volumes, backlog conversion and operating leverage, with FY revenue growth around the midpoint of company guidance and profitability near its upper end. AI-driven data-centre construction, electrification and rising power demand support gas turbine and grid investment, while SE’s substantial backlog provides strong earnings visibility. In our view, elevated activity can continue for years, but the cycle is unlikely to last indefinitely. Slower AI adoption, weaker returns on investment, higher interest rates and a softer economy could gradually weigh on new orders. SE is an excellent company, but we believe its valuation still assumes an unusually long-lasting supercycle. Despite the recent share price decline, we continue to see the shares as too expensive. We reiterate our SELL rating and EUR 100.00 PT. The full update can be downloaded under https://research-hub.de/companies/siemens-energy-ag
Thu, 15.10.2026       https://research-hub.de/companies/cicor-technologies-ltd

Cicor’s Q3 revenue of CHF 170.8m came in around 6% below both consensus of CHF 182.1m and our CHF 181m estimate, while organic growth of 4.6% also missed consensus of 7.7%. The shortfall was mainly driven by material shortages, not weaker demand. Order intake rose 10.7% to CHF 193.2m, slightly above consensus, with bookto-bill at 1.13x. Management expects a sharp Q4 acceleration, supported by the strong backlog and A&D program ramp-ups, and stated that no additional orders are required to support the Q4 plan. We therefore continue to see the issue primarily as one of revenue timing. We make only minor estimate changes, shifting some revenue and earnings into 2027. BUY, PT CHF 180.00. The full update can be downloaded under https://research-hub.de/companies/cicor-technologies-ltd
Thu, 15.10.2026       https://research-hub.de/companies/draegerwerk-ag-co-kgaa

Dräger reported preliminary Q3 2026 results showing modest top-line growth but weaker operating profitability, despite a significant positive contribution from customsduty refunds. While the underlying margin development was disappointing, strong order intake in Safety Technology, the traditionally pronounced Q4 earnings seasonality and the recently removed FDA restrictions on US patient monitoring support our confidence in the medium-term investment case. We lower our FY26 earnings estimates to reflect the weaker-than-expected Q3 performance but leave our medium-term assumptions and EUR 135.00 price target unchanged. BUY. Dräger will host a Capital Markets Day on November 18, (hybrid), and professional and institutional investors as well as analysts are invited to register: https://research-hub.de/events/registration/2026-11-18-10-00/DR0-GR The full update can be downloaded under https://research-hub.de/companies/draegerwerk-ag-co-kgaa
Thu, 15.10.2026       https://research-hub.de/companies/kion-group-ag

KION cut its FY26 guidance yesterday after reporting preliminary Q3 numbers below consensus. Adjusted EBIT of c. EUR 203m (+7% yoy) missed consensus of EUR 211m and our c. EUR 209m. ITS fell short, while IAS delivered, in which we see the better capability of IAS to pass on costs. KION attributes the cut mainly to Q3 ITS order intake, which did not develop as expected. Group adj. EBIT is now guided at EUR 815-875m (old EUR 880-980m), and the midterm target has been pushed beyond 2027. The new midpoint of EUR 845m matches the EUR 844m we have modelled since the pre-close. Although we had already modelled the low end of the old ITS range, we cut our ITS estimates further and trim our earnings estimates slightly. We expect more details on the Q3 call on 29 October, including on the midterm targets. We leave our PT at EUR 51.00 and reiterate BUY, as the valuation stays undemanding at c.6x EV/EBITDA 2027E and c.8x P/E 2027E. The full update can be downloaded under https://research-hub.de/companies/kion-group-ag
Thu, 15.10.2026       https://research-hub.de/companies/infineon-technologies-ag

We expect Infineon to deliver a solid Q4 on 10 November, with limited scope for a material surprise as attention shifts to the FY27 outlook. Strong AI power demand, improving industrial conditions and higher utilization should drive a meaningful acceleration in earnings, although our FY27 revenue growth and margin forecasts remain below consensus. We see scope for management to raise its FY27 AI revenue ambition to EUR 3.0bn, supported by sustained demand, capacity expansion and improved pricing. However, Dresden ramp-up costs, persistent automotive headwinds and an uneven industrial recovery could constrain margin expansion. With the stock trading at ~16.0x 2027E EV/Segment Result, already reflecting a substantial earnings recovery, we believe a sustained re-rating will depend on stronger margin conversion beyond AI. We reiterate HOLD with a EUR 60.00 price target. The full update can be downloaded under https://research-hub.de/companies/infineon-technologies-ag
Thu, 15.10.2026       https://research-hub.de/companies/blue-cap-ag

Blue Cap is expected to publish its H1 26 results on 20 October. We forecast revenues of approximately EUR 65m and adjusted EBITDA of EUR 2.7m, down significantly, versus the reported H1 25 figures. These declines primarily reflect the changed portfolio perimeter following the disposal of con-pearl, while Janoschka should contribute only marginally following its June closing. Across the existing portfolio, we expect broadly stable sequential revenues and modest profitability. With Janoschka’s main earnings contribution still ahead, we expect confirmation of FY26 guidance. We retain our full-year estimates and reiterate BUY with an unchanged PT of EUR 33.00. The full update can be downloaded under https://research-hub.de/companies/blue-cap-ag
Wed, 14.10.2026       https://research-hub.de/companies/vossloh-ag

Vossloh will publish its Q3 results next week, on October 22. We expect yoy revenue growth and an increase in EBIT, with Sateba's acquisition-related PPA and integration effects continuing to weigh on profitability. However, we view 2026 as a transition year, with the full benefits of integration and synergies expected to become more visible in 2027. At the same time, Vossloh is well positioned to benefit from the global rail infrastructure investment cycle, driven by network modernization and capacity expansion, as already reflected in strong H1 order intake. Following a nearly 45% share price decline from its peak, we see an attractive entry opportunity for patient, long-term value investors. In our view, the decline reflects market impatience rather than operational weakness. The valuation looks particularly attractive when considering management's FY30 targets and the stability of the rail infrastructure market. We reiterate our BUY rating with a PT of EUR 90.00, implying upside potential of 88%. The full update can be downloaded under https://research-hub.de/companies/vossloh-ag
Wed, 14.10.2026       https://research-hub.de/companies/viscom-se

We expect Viscom's Q3 results to confirm the ongoing recovery, with order intake of around EUR 22m, sales of EUR 23m and EBIT of EUR 1.5-2.0m, broadly sustaining the profitability achieved in Q2. However, the EUR 4m Q1 loss continues to weigh on fullyear earnings, and even our revised 2% FY26 EBIT margin assumption requires a further improvement in Q4, leaving limited scope for the upper end of management's guidance. Encouragingly, demand is recovering across core industrial and automotive applications, particularly in Asia and North America, while AI-related inspection and the sizeable battery-cell contract provide additional growth opportunities beyond 2026. With the backlog supporting near-term revenue visibility, the key question is whether improving volumes can translate into stronger margins. At 7.4x 2027E EV/EBITDA, we believe the valuation does not fully reflect the medium-term earnings recovery potential. We reiterate BUY with a EUR 8.00 price target. The full update can be downloaded under https://research-hub.de/companies/viscom-se
Wed, 14.10.2026       Lang & Schwarz AG

Company Name: Lang & Schwarz AG ISIN: DE000LS1LUS9   Reason for the research: Initiation Recommendation: BUY Target price: EUR 20 Target price on sight of: 12 months Last rating change: Analyst: Simon Keller Trading the retail renaissance; INITIATE WITH BUYThe market is pricing Lang & Schwarz as if its story ended with Tr [ … ]
Wed, 14.10.2026       https://research-hub.de/companies/fresenius-medical-care-ag

Fresenius Medical Care (FME) reaffirmed its FY26 guidance, although fading TDAPA benefits, weak US treatment volumes and restructuring charges could pressure H2 earnings. We cut our FY26 revenue estimate by 2.5% to EUR 19.04bn and EBIT by 10.7% to EUR 1.66bn. Ongoing share buybacks, which reduced outstanding shares by 7.1% YTD, should partly offset earnings pressure at the EPS level. Despite near-term challenges, operational efficiencies and cash generation remain supportive. Following a 16% share price decline since August, valuation appears increasingly attractive. Reflecting the lower share count and updated valuation assumptions, we raise our price target to EUR 46.00 from EUR 44.00 and upgrade our rating from HOLD to BUY. The full update can be downloaded under https://research-hub.de/companies/fresenius-medical-care-ag

Gamechanger in online marketing · Innovation as a service · Upgrade your own internet presence.

© 2026 Select Sector SPDRs

* * *

More Sector related Investment Ideas
© 2026 WEBs Investments ETFs
Legend/Explanation
The newswire feed is updated several times a day. To make sure you don't miss any news, please check back here often. If you are curious about a headline or want to find out more about a publication, click on it to go to the preview and click again to go to the full news item.
Member of 3R/RSQ Network
Digital Content
Network Alliance
Transparency - Reliability - Credibility
Information regarding Product Information
Sunday, 22.11.2026, Calendar Week 47, 326th day of the year, 39 days remaining until EoY.